title: Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals.
abstract: OBJECTIVE
  To evaluate the long-term effects of different boosted protease inhibitors (bPIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral regimens on lipid levels in HIV seropositive individuals who have not received lipid-lowering agents.
  
  
  METHODS
  Data consisted of 595 patients participating in the population-based Athens Multicenter Cohort Study who were consistently followed up during 1996-2008.
  
  
  RESULTS
  In naïve patients, lipid parameters increased sharply during the first 3 months of antiretroviral therapy and reached a plateau level approximately 6-9 months after therapy initiation. The plateau levels remained almost stable for up to 3.5 years. In general, bPIs exerted a more pronounced effect compared to NNRTIs.
  
  
  CONCLUSIONS
  The administration of PI- or NNRTI-based regimens especially in naïve but also in unboosted PI experienced patients provoked a sharp increase in lipid levels that remained stable in higher levels for more than 3 years.
authors.affiliation: Fourth Department of Internal Medicine, Athens Medical School, Attikon University General Hospital, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Papadopoulos
authors.forename: N
authors.initials: N
authors.lastname: Pantazis
authors.forename: P
authors.initials: P
authors.lastname: Panagopoulos
authors.forename: S
authors.initials: S
authors.lastname: Kourkounti
authors.forename: G
authors.initials: G
authors.lastname: Xylomenos
authors.forename: M
authors.initials: M
authors.lastname: Chini
authors.forename: G
authors.initials: G
authors.lastname: Petrikkos
authors.forename: H
authors.initials: H
authors.lastname: Sambatakou
authors.forename: P
authors.initials: P
authors.lastname: Ioannidou
authors.forename: T
authors.initials: T
authors.lastname: Kordosis
authors.forename: G
authors.initials: G
authors.lastname: Panos
authors.forename: G
authors.initials: G
authors.lastname: Touloumi
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D006115:Greece / Q000453:epidemiology; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D017320:HIV Protease Inhibitors; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors